Abstract: The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.
Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.
Type:
Grant
Filed:
June 3, 2015
Date of Patent:
October 4, 2016
Assignee:
INFLARX GMBH
Inventors:
Renfeng Guo, Niels Christoph Riedemann, Yan Li, Beifen Shen
Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.
Type:
Grant
Filed:
June 27, 2014
Date of Patent:
July 7, 2015
Assignee:
INFLARX GMBH
Inventors:
Renfeng Guo, Niels Cristoph Riedemann, Yan Li, Beifen Shen
Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.
Type:
Grant
Filed:
November 26, 2010
Date of Patent:
August 12, 2014
Assignee:
Inflarx GmbH
Inventors:
Renfeng Guo, Niels Christoph Riedemann, Yan Li, Beifen Shen